Linaclotide
Brand name: Linzess
Rank #27 of 500 drugs by total cost
$639.4M
Total Cost
823,023
Total Claims
$639.4M
Total Cost
23,483
Prescribers
$777
Cost per Claim
133,250
Beneficiaries
1,181,116
30-Day Fills
$27K
Avg Cost/Provider
35
Avg Claims/Provider
About Linaclotide
Linaclotide (sold as Linzess) was prescribed 823,023 times by 23,483 Medicare Part D providers in 2023, costing the program $639.4M. At $777 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology